Bristol Myers Squibb’s Post

i3 Health is excited to invite you to four live #webinars where esteemed professionals will explore the latest advancements and effective management strategies of Mantle cell lymphoma, Multiple myeloma, Cold agglutinin disease, and aTTP! Learn more here: https://bit.ly/3WHINit #MantleCellLymphoma #MultipleMyeloma #ColdAgglutininDisease #aTTP #MedicalEducation #CancerResearch #Hematology #OncologyUpdates

i3 Health is excited to invite you to four live #webinars where esteemed professionals will explore the latest advancements and effective management strategies of Mantle cell lymphoma, Multiple myeloma, Cold agglutinin disease, and aTTP! Learn more here: https://bit.ly/3WHINit #MantleCellLymphoma #MultipleMyeloma #ColdAgglutininDisease #aTTP #MedicalEducation #CancerResearch #Hematology #OncologyUpdates

You're invited! i3 Health is excited to invite you to exciting #webinars where esteemed professionals will explore the latest advancements and effective management strategies of Mantle cell lymphoma, Multiple myeloma, and Cold agglutinin disease. Learn more here: https://bit.ly/3WHINit #MantleCellLymphoma #MultipleMyeloma #ColdAgglutininDisease #aTTP #MedicalEducation #CancerResearch #Hematology #OncologyUpdates

📢Just published! Explore the latest review of the 5th edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues (WHO-HEM5), offering insights into lymphoblastic leukemia/lymphoma, multiple myeloma, and more. Key topics: 1️⃣Classification and pathogenesis, 2️⃣Pathogenesis and diagnostic considerations, 3️⃣Dendritic cell lesions, 4️⃣Diagnostic approaches. More in the article: https://ow.ly/uxk750QRgoE #MedEd #MM

🚀 Groundbreaking insights from EHA 2024! Prof Alexey Danilov from City of Hope National Medical Center presented a study comparing the efficacy and safety of bispecific antibodies EPCOR, MOSUN, and ODRO in patients with relapsed/refractory follicular lymphoma (R/R FL). This matching-adjusted indirect comparison sheds light on the potential benefits of these treatments for patients after at least two systemic therapies. Discover these updates.👇 For all EHA 2024 videos, find the link in the comments! #MediMix #EHA2024 #Hematology #FollicularLymphoma #CancerResearch #Innovation

#HighlyCitedPapers   📝 Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells — Arena, et al.   In this paper, the authors studied the pharmacologic inhibition and silencing of c-MYC in multiple myeloma and primary effusion lymphoma cell lines.   Full text is available 👇 https://lnkd.in/ddMaRc_b   #medicine #health #research #science

On the heels of the American Society of Hematology (#ASH) 2024 Annual Meeting, excited to see our RWE study titled "B-CD30+ HOdgkin Lymphoma International Multi-center Retrospective Study of Treatment PractIces and OutComes (B-HOLISTIC)" published this past week. The primary study described the real-world treatment patterns and clinical outcomes in 1703 patients with relapsed/refractory Hodgkin Lymphoma (HL) and frontline classical HL in 12 countries across East Asia, Latin America, the Middle East, South Africa, Russia, and Australia. This current subgroup analysis focused specifically on the Middle East region and South Africa. Thank you to the patients, co-authors (David Brittain, Saad Akhtar, Sylvia Rodrigues, Moosa Patel, Dhaya Moodley, Jaimendra Prithipal Singh, Lydia M. Dreosti, Zainab Mohamed, Mubarak Al-Mansour, Mohsen Alzahrani, M. Shahzad Rauf, Irfan Maghfoor, Sevgi Kalayoğlu Beşışık, Can Boğa, Güray Saydam, Zhongwen Huang and Burhan Ferhanoğlu) and my Takeda Colleagues. https://lnkd.in/ehhU5Qbu #ASH24 #ASH2024 #Hematology #Haematology

It highlights advanced techniques such as circulating tumor DNA (ctDNA) analysis and their potential clinical applications in diagnosis, prognosis, and monitoring treatment response. . #liquidbiopsy #tcell #lymphoma . ℹ️ Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application

Ari Melnick, from Weill Cornell Medicine, talked at the Presidential Symposium at European Hematology Association (EHA) 2024 about the unmet needs in the lymphoma field, focusing on the lack of understanding of the cells that give rise to lymphomas, their mutation patterns, and the potential for precise immunotherapy. He also emphasized the need for inclusive research that addresses disparities in knowledge and treatment efficacy among different patient populations. 🔗See more from our coverage from EHA 2024: https://lnkd.in/dGGgc_CW #EHA #Hematology

The #nonhodgkinlymphoma market is expected to witness significant growth during the forecast period. The global #paediatric hodgkin lymphoma market is majorly driven by high prevalence of non-hodgkin lymphoma, increases in number of promising pipeline #drugs, high diagnostics rate and vulnerable paediatric population. To know more, visit https://lnkd.in/gzC_Mw36 #DBMR #NonHodgkinLymphoma #NHL #LymphomaAwareness #CancerResearch #Lymphoma #BloodCancer #CancerSupport #LymphomaWarrior #CancerTreatment #Hematology #DBMRInsights